DexCom (NASDAQ:DXCM) PT Raised to $86.00

DexCom (NASDAQ:DXCM) had its price objective hoisted by research analysts at Sanford C. Bernstein from $82.00 to $86.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “outperform” rating on the medical device company’s stock. Sanford C. Bernstein’s target price points to a potential upside of 17.10% from the company’s previous close.

DXCM has been the topic of several other reports. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. Wells Fargo & Company lifted their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday. BTIG Research decreased their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Finally, Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Six analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Trading Down 1.9 %

DXCM opened at $73.44 on Friday. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The business has a fifty day simple moving average of $70.11 and a 200-day simple moving average of $98.24. The firm has a market cap of $29.21 billion, a P/E ratio of 47.38, a P/E/G ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $994.20 million during the quarter, compared to analysts’ expectations of $991.55 million. DexCom had a return on equity of 31.41% and a net margin of 16.95%. On average, equities analysts expect that DexCom will post 1.69 earnings per share for the current year.

Insider Activity at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock valued at $126,390 over the last ninety days. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. New York State Teachers Retirement System grew its holdings in shares of DexCom by 1.6% during the third quarter. New York State Teachers Retirement System now owns 366,308 shares of the medical device company’s stock worth $24,557,000 after buying an additional 5,804 shares during the last quarter. Avitas Wealth Management LLC grew its stake in shares of DexCom by 20.2% in the 3rd quarter. Avitas Wealth Management LLC now owns 6,475 shares of the medical device company’s stock valued at $434,000 after purchasing an additional 1,086 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of DexCom by 103.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,306 shares of the medical device company’s stock valued at $356,000 after purchasing an additional 2,692 shares during the period. abrdn plc raised its stake in shares of DexCom by 28.4% during the third quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock worth $25,842,000 after purchasing an additional 85,174 shares during the last quarter. Finally, Semanteon Capital Management LP acquired a new stake in shares of DexCom during the third quarter worth $922,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.